医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Exscientia to Report Third Quarter 2021 Financial Results on November 17, 2021

2021年11月10日 PM10:00
このエントリーをはてなブックマークに追加


 

OXFORD, England

Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will report financial results for the third quarter ended September 30, 2021, on Wednesday, November 17, 2021 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. ET on Thursday, November 18, 2021, to provide additional detail on the different business models underlying the company’s pipeline of more than 25 programmes.

A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (760) 294 1674 (U.S.), +44 203 059 5869 (U.K.), +44 203 059 8128 (International) and mentioning Exscientia. A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.

Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005488/en/

CONTACT

Investors:

Sara Sherman

investors@exscientia.ai

Media:

Amanda Galgay

media@exscientia.ai

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Dr. Ravi Karra Joins Advanced Clinical to Accelerate Global Growth and Deliver Innovative Oncology Trials
  • LevitasBio补强公司高级管理层
  • レビタスバイオが経営幹部を強化
  • Eleven NTT Papers Selected for NeurIPS 2022
  • Sonic Healthcare战略性入股Microba Life Sciences,建立重大商业合作关系